Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy

Medicine (United States)

Volumn 96, Issue 15, 2017, Pages

  Qiao, Yong Chao ^a,b   Chen, Yin Ling ^a   Pan, Yan Hong ^a   Ling, Wei ^a   Tian, Fang ^b   Zhang, Xiao Xi ^a   Zhao, Hai Lu ^a,b  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

case control study; diabetic nephropathy; meta analysis; transforming growth factor beta 1; type 2 diabetes mellitus

Indexed keywords

ALBUMIN; CREATININE; TRANSFORMING GROWTH FACTOR BETA1; BIOLOGICAL MARKER; TGFB1 PROTEIN, HUMAN;

ALBUMINURIA; CASE CONTROL STUDY; CHINESE; CLINICAL EVALUATION; CNKI DATABASE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; ETHNICITY; HUMAN; MACROALBUMINURIA; MEDLINE; MICROALBUMINURIA; NEWCASTLE-OTTAWA SCALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PUBLISHING; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; WANFANG DATABASE; BLOOD; COMPLICATION; DIABETIC NEPHROPATHIES; FEMALE; MALE; META ANALYSIS; URINE;

ALBUMINURIA; BIOMARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85017645018     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006583     Document Type: Review

References (51)

1. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137-49.
2. Packham DK, Alves TP, Dwyer JP, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 2012;59:75-83.
3. Satirapoj B, Kaewput W, Supasyndh O, et al. Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial. J Diabetes Res 2015;2015: 172038.
4. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.
5. de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369: 2492-503.
6. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40.
7. Lv C, Zhou YH, Wu C, et al. The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy. Diabetes/Metab Res Rev 2015;31:717-24.
8. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008;19:433-42.
9. Korpinen E, Groop PH, Fagerudd JA, et al. Increased secretion of TGFbeta1 by peripheral blood mononuclear cells from patients with type 1 diabetes mellitus with diabetic nephropathy. Diabetic Med 2001;18: 121-5.
10. Iwano M, Kubo A, Nishino T, et al. Quantification of glomerular TGFbeta 1 mRNA in patients with diabetes mellitus. Kidney Int 1996; 49:1120-6.
11. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Investig 1992;90:1-7.
12. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92.
13. Hellmich B, Schellner M, Schatz H, et al. Activation of transforming growth factor-beta1 in diabetic kidney disease. Metab Clin Exp 2000; 49:353-9.
14. Ibrahim S, Rashed L. Estimation of transforming growth factor-beta 1 as a marker of renal injury in type II diabetes mellitus. Saudi Med J 2007;28:519-23.
15. Shaker OG, Sadik NA. Transforming growth factor beta 1 and monocyte chemoattractant protein-1 as prognostic markers of diabetic nephropathy. Hum Exp Toxicol 2013;32:1089-96.
16. Rivarola EW, Moyses-Neto M, Dantas M, et al. Transforming growth factor beta activity in urine of patients with type 2 diabetes and diabetic nephropathy. Braz J Med Biol Res 1999;32:1525-8.
17. Upadhyaya S, Kadamkode V, Mahammed R, et al. Adiponectin and IL-6: mediators of inflammation in progression of healthy to type 2 diabetes in Indian population. Adipocyte 2014;3:39-45.
18. Qiao YC, Shen J, Hong XZ, et al. Changes of regulatory T cells, transforming growth factor-beta and interleukin-10 in patients with type 1 diabetes mellitus: A systematic review andmeta-analysis. Clin Immunol 2016;170:61-9.
19. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12.
20. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011; Available at: http://www.ohri.ca/programs/clinical-epidemiology/ oxford.asp. Accessed August 20, 2016.
21. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-37.
22. Higgins JP, Thompson SG. Quantifying heterogeneity in ameta-analysis. Stat Med 2002;21:1539-58.
23. Qiao YC, Shen J, He L, et al. Changes of regulatory T cells and of proinflammatory and immunosuppressive cytokines in patients with type 2 diabetes mellitus: a systematic review andmeta-analysis. J Diabetes Res 2016;2016:3694957.
24. Liu S, Tian J, Bao HL, et al. Infect of pingshen decoction on serum HGF, Cys C and TGF-beta1 diabetic nephropathy in early stage. J Immunol Res 2014;39:1128-31.
25. Jun-Wen D, Tao W, Guo-Zhen N. The level about the TGF-b1 and proto-oncogene proteins c-sis in peripheral blood of T2DM patients with nephropathy and the clinical applications (in Chinese). Clin Focus 2007;22:793-4.
26. Chi DZ. Association of serum transforming growth factor-(TGF-b1), type IV collagen and laminin with diabetic nephropathy in type 2 diabetic patients (in Chinese). Heilongjiang Med J 2013;26:402-7.
27. Changxin F. Clinical significance of determination of serum cystatin C, transforming growth factor beta1(TGF-b1) and urine microalbumin levels in patients with DM2 nephropathy (in Chinese). J Radionimmunol 2007;20:471-4.
28. Jing C-y, Ye S-d, Chen Y. The change of serum and urinary transforming growth factor-beta-1 and their clinical significances in type 2 diabetics (in Chinese). Chin J Lab Diagn 2005;9:286-9.
29. Zhen-zuo L, Lin L, Rui-yan X. Clinical study of serum matrix metalloproteinase-9 and transforming growth factor-b1 related with type 2 diabetic patients with nephropathy (in Chinese). J Taishan Med Coll 2005;26:530-4.
30. Rui-ji L, Lan-ji L. The level about the HGF and TGF-b1 in peripheral blood of T2DM patients with nephropathy and the clinical applications (in Chinese). Hebei Med J 2011;33:1806-8.
31. Yan-jun W, Ping H, Li-ping L. Determination and clinical significance analysis of IL-6, TNF-b and TGF-b1 in the patients with diabetic nephropathy (in Chinese). Chin J Sci Techn Periodicals 2002;18:214-5.
32. Ye-Sheng W, Yan L, Yan-Wu Y. The serum level and the genotype of TGF-b1 in patients with type 2 diabetic nephropathy (in Chinese). Chin J Lab Med 2005;128:173-8.
33. Wei-jie Z, Kai L. Association between changes in transforming growth factor-beta1 level and type 2 diabetic nephropathy (in Chinese). J Clin Rehabil Tissue Eng Res 2007;11:9838-42.
34. Zhou Y, Su X, Ke S. Relationship between serum levels of transforming growth factor-b1, tumor necrosis factor-b and diabetic nephropathy (in Chinese). Acta Med Univ Sci Technol Huazhong 2005;34:441-4.
35. Ha SW, Kim HJ, Bae JS, et al. Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy. Diabetes Res Clin Pract 2004;65:167-73.
36. Chun-Yan J, Shan-Dong Y, Yan C. Clinical significance of urinary transforming growth factor-b1 measurement in diabetics (in Chinese). Acta Univ Med Nahui 2003;38:202-5.
37. Yun-hai S. Clinical significance of Urinary transforming growth factorb1 measurement in type 2 diabetic nephropathy. J Radionimmunol 2013;26:743-4.
38. Jian-jian Y, Yun-juan Q, Qi L, et al. Urinalysis of transforming growth factor-b1 in old patients with diabetic nephropathy. Chin J Rehabil Theory Pract 2005;11:940-1.
39. Dong C, Wen-ruo D, Jian-bin L, et al. Correlation of serum TGF-b1 and PDGF-BB with albumin excretion rate in patients with type 2 diabetic nephropathy (in Chinese). Acta Acad Med Qingdao Univ 2011;47: 450-9.
40. Jian-hong J, Yue-zhi H, Yan W, et al. The change and the implication of urinary VEGF, TGFb1 and Co-IV level in type 2 diabetic patients with nephropathy (in Chinese). Bull Med Res 2004;33:16-20.
41. Wei-min L, Kui X. The detection and clinical significance of serum and urinary transforming growth factor-b1 measurement in type 2 diabetic nephropathy (in Chinese). Clin Focus 2004;19:1362-3.
42. Tao M. The correlation research about urinary microalbuminuria, and TGF-b1 in early diabetic nephropathy (in Chinese). J Pract Med 2006; 22:399-400.
43. Wei-kang Z. Clinical significance of determination of transforming growth factor beta 1, tumor necrosis factor alpha and urine microalbumin levels in patientswithDM2nephropathy (in Chinese). J Clin Res 2008;25:972-5.
44. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001;109(suppl 2):S424-37.
45. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003;23:532-43.
46. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007;132:2169-80.
47. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008;79(8 suppl):1527-34.
48. Yamamoto T, Nakamura T,Noble NA, et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993;90:1814-8.
49. Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997;46:854-9.
50. Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin N Am 2004;88:1001-36. xi.
51. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-51.